Quantcast
Skip to content

SARS-CoV-2 variants are escaping neutralizing antibody responses, but have not escaped the T-cell response – A Johnson & Johnson Case Study

Available On-Demand

To understand immune evasion of emerging variants and vaccine responses, researchers need to go beyond the antibody response and study the T-cell immune response to SARS-CoV-2. T cells generate immune responses to various regions of the SARS-CoV-2 virus, providing a more comprehensive understanding of the immune response in COVID-19.

In this webinar, Dr. Harlan Robins, CSO & Co-founder, Adaptive Biotechnologies, will discuss a peer-reviewed study published in Nature, which used the immunoSEQ® T-MAP™ COVID technology to measure the T-cell immune response, induced by the Ad26.COV2.S COVID-19 vaccine, and quantify T-cell expansion across all regions of the SARS-CoV-2 virus, including the spike protein.

For Research Use Only. Not for use in diagnostic procedures.

Harlan-Headshot-sq-circle

Harlan Robins, PhD

Chief Scientific Officer & Co-Founder
Adaptive Biotechnologies

Webinar brought to you by:

SEQdiscovery

Adaptive Biotechnologies Logo SMl

SARS-CoV-2 variants T-cell response - A Johnson & Johnson Case Study
Scroll To Top
Share via
Copy link